Pittsburgh, PA, May 24 2021 (Bizjournals) — Noveome Biotherapeutics Inc. on Monday named Christopher J.P. Velis as its CEO.
Velis replaces William Golden, who founded the Pittsburgh-based biopharmaceutical company and who remains chairman. Velis, who joined the company’s board in March, is a 27-year veteran of the industry and has extensive experience in medical devices and biopharmaceuticals.
“We are thrilled to have Chris take on this additional role as our new CEO,” said Golden in a statement. “His vast experience in innovative medical technologies will help guide Noveome as it continues to develop and commercialize its novel platform biologic ST266.”
ST266 is the drug candidate for Noveome, which develops biologics that repair damaged tissues. ST266 completed a phase-two clinical trial to treat persistent corneal epithelial defects.